Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1991;17:643-651

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Charles, C. J.
Right arrow Articles by Sybertz, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Charles, C. J.
Right arrow Articles by Sybertz, E. J.

Hypertension, Vol 17, 643-651, Copyright © 1991 by American Heart Association


ARTICLES

Hemodynamic and hormonal effects of neutral endopeptidase inhibitor SCH 39370 in sheep

CJ Charles, EA Espiner, VA Cameron, AM Richards, TG Yandle and EJ Sybertz
Department of Endocrinology, Princess Margaret Hospital, Christchurch, New Zealand.

Whole body clearance of atrial natriuretic factor is due to both receptor uptake and enzymatic degradation initiated by neutral endopeptidase 24.11. The effects of neutral endopeptidase inhibition have been studied in seven sodium-replete sheep using SCH 39370, a specific and potent inhibitor of neutral endopeptidase, in the presence or absence of exogenous hormone [rat ANF-(101-126), 2.4 pmol/kg/min for 2 hours]. SCH 39370 alone (2.5 mg/kg bolus) increased plasma atrial natriuretic factor and plasma cyclic GMP levels, lowered arterial pressure for periods beyond changes in plasma atrial natriuretic factor or cyclic GMP, and suppressed both plasma aldosterone and cortisol levels when compared with vehicle injections. The effects of SCH 39370 were similar to or exceeded those of atrial natriuretic factor infusions, which induced significantly greater increases in plasma atrial natriuretic factor (p = 0.01). Neither agent alone was natriuretic. When SCH 39370 and atrial natriuretic factor were given together, plasma cyclic GMP but not atrial natriuretic factor levels were increased (p = 0.013) compared with atrial natriuretic factor infusion alone, and the half-life was prolonged (p = 0.002) in the presence of SCH 39370. The hypotensive response was greater than that induced by atrial natriuretic factor alone (p = 0.03) but not different from SCH 39370 alone. Inhibitory effects of SCH 39370 on aldosterone levels were similar in the presence of absence of exogenous atrial natriuretic factor.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
M. W. TAAL, V. D. NENOV, W. WONG, S. R. SATYAL, O. SAKHAROVA, J. H. CHOI, J. L. TROY, and B. M. BRENNER
Vasopeptidase Inhibition Affords Greater Renoprotection than Angiotensin-Converting Enzyme Inhibition Alone
J. Am. Soc. Nephrol., October 1, 2001; 12(10): 2051 - 2059.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. J. Charles, E. A. Espiner, A. M. Richards, and E. J. Sybertz
Endopeptidase Inhibition in Angiotensin-Induced Hypertension : Effect of SCH 39370 in Sheep
Hypertension, July 1, 1995; 26(1): 89 - 94.
[Abstract] [Full Text]